Key Takeaways
- Revenue up 21%, margin down sharply: Standalone revenue grew 21% YoY as higher raw material costs were passed on, but logistics and energy costs could not be fully passed through, compressing the bottom line.
- ATBS destocking delayed the recovery: ATBS demand did not pick up as anticipated in H1 because of customer destocking, pushing the expected volume recovery into H2.
- Two new capex cycles announced: A ₹500 cr specialty chemicals capex was committed, with an additional ₹500 cr under evaluation; together they signal a pivot toward adjacencies in fragrances, personal care, and water treatment.
- VOPL ramp-up pushed out again: Internal production problems and a re-engineering process have delayed the VOPL contribution; revenue this year is now guided to ₹75 cr–₹100 cr, below earlier expectations.
- What to watch next quarter: Whether the ATBS volume uptick materializes in Q3 as promised, the pace of logistics cost cooling, and any concrete progress on land acquisition for the second capex tranche.
ATBS: The Delayed Recovery
- H1 miss: ATBS demand did not pick up as anticipated at the start of FY27 because of destocking by customers, which prevented the company from meeting its half-year target.
- Q3 turning point: Management is seeing a meaningful improvement in volumes, with Q3 itself looking strong on an uptick in demand; the recovery is now expected through the second half.
- Pricing alongside volumes: Better volumes are expected in Q3, Q4 FY27 and into next year, along with improved pricing, according to management.
Vinati Saraf Mutreja: "In fact, we are seeing a meaningful improvement in volumes, with Q3 itself looking strong, with an uptick in demand for ATBS. So we definitely are going to see some recovery through the second half."
Margin Pressure & the Pass-Through Gap
- EBITDA margin fell to 21%: The Q2 margin decline was driven by a shift of ATBS sales from Q2 into Q3 and Q4, plus logistics and power cost increases that were not fully passed on to customers. Raw material cost increases were largely passed on.
- Logistics costs now easing: Logistics rates have started cooling in Q3, with further reduction expected in Q4, which should positively impact profitability in the second half.
- FY27 margin guided to 24%–25%: Management expects the full-year EBITDA margin to land in that range, with FY28 improving to 25%–26%.
Gulshan Sakhuja: "You can say the worst is now behind us."
VOPL: Delayed Again, Smaller Near-Term Contribution
- Revenue downgraded: VOPL revenue this year is now expected at ₹75 cr–₹100 cr, below earlier expectations, because internal production problems and a re-engineering process are taking longer than planned.
- Five-product portfolio: VOPL spans MEHQ, guaiacol, anisole, 4-methoxyacetophenone, and isoamylene-based products (tertiary amyl alcohol, PTAP); revenue from the isoamylene-based products is expected to start from December/January.
- Streamlining timeline: The re-engineering process is expected to be completed by April/May of the next financial year (FY28), after which VOPL is expected to contribute meaningfully to both consolidated top line and bottom line.
- MEHQ specifics: Manufacturing has started at lower volume and output is being self-consumed to make BHA; commercial sales are expected from April, with ramp-up to optimum utilization taking about one year as customer evaluations and qualifications are underway.
- MEHQ in context: Management views current competitive pressure on MEHQ as temporary, notes gross margin on the product itself remains high, and points out that MEHQ is just ₹100 cr of an expected ₹3,000 cr–₹4,000 cr total company revenue in the next 2–3 years.
New Capex: Two Tranches, Adjacent Chemistry
- First ₹500 cr committed: A capex plan to develop and commercialize new specialty chemicals with applications in fragrances, personal care, water treatment, oil fields, and resins; commercialization is expected in two years.
- Second ₹500 cr under evaluation: An additional ₹500 cr investment is being planned, with land acquisition underway; management will provide more clarity in the next couple of months, and it may not happen at all.
- Product and market profile: The new products are related to existing products with backward, forward, or horizontal integration; they have been tested over the last year; most are for export (65%–70%); and in two of three major product segments, Vinati will be a fairly large player.
- Execution confidence: Management says it has learned from past project execution mistakes and is better positioned on which agencies to hire; commissioning and scale-up are expected to be smoother with more confident suppliers, technology, and process engineers.
- Financial expectations: Asset turnover is expected at 1:1 to 1.5x, ROI at 15%–20%, and the EBITDA margin profile is expected to be similar to existing business at 25% or above.
Vinati Saraf Mutreja: "These products are related to our existing products. There is some sort of integration, some sort of adjacencies, whether backward, forward, or horizontal. We have been testing these products over the last year, so we are quite confident in implementing them, and hence we have announced them."
Segment-Level Performance
| Segment | Trend | Commentary |
|---|---|---|
| ATBS | ▼ Soft H1, ▲ H2 expected | Destocking delayed the recovery; meaningful volume improvement seen entering Q3, with better volumes expected through H2 and into next year. |
| Butyl Phenol | ▬ Stable | Delivered stable performance; better performance anticipated in H2 supported by improving demand conditions. |
| Antioxidant | ▲ Strong | Delivered strong performance in H1 despite a challenging market environment; expected to maintain momentum in H2 supported by market expansion. |
| IB | ▲ Strong | Reported strong performance during H1; strong performance expected to continue in H2. |
| IBB | ▲ Strong | Delivered strong performance in H1 in terms of both volume and pricing; similar strong performance expected in H2. |
| VOPL | ▼ Delayed | Internal production problems and re-engineering pushed the ramp-up out; FY27 revenue guided to ₹75 cr–₹100 cr, with meaningful contribution only after streamlining by April FY28. |
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| ATBS volume recovery | Meaningful improvement in volumes, with Q3 already looking strong | H2 FY27 |
| Logistics cost tailwind | Logistics rates started cooling in Q3, further reduction expected in Q4 | Q3 and Q4 FY27 |
| FY27 revenue growth | 20%–25% improvement over previous year | FY27 full year |
| FY27 EBITDA margin | 24%–25% | FY27 full year |
| FY28 EBITDA margin | 25%–26% | FY28 full year |
| VOPL streamlining | Re-engineering complete, meaningful top-line and bottom-line contribution begins | April/May FY28 |
| MEHQ commercial sales | Commercial sales begin, ramp-up to optimum utilization within one year | Starting April FY28 |
| First ₹500 cr capex commercialization | New specialty chemicals plants operational | Within two years |
| Second ₹500 cr capex decision | Clarity after land acquisition and pilot trials complete | Within six months |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Standalone net income (incl. other income) | ₹681 cr, down 4% QoQ from ₹707 cr in Q1 FY27 |
| Standalone net income (incl. other income) | ₹707 cr, up 21% YoY from ₹562 cr in Q2 FY26 |
| Standalone EBITDA | ₹142 cr, down 27% YoY from ₹195 cr in Q2 FY26 |
| Standalone PAT | ₹87 cr, down 33% YoY from ₹129 cr in Q2 FY26 |
| Consolidated net income (incl. other income) | ₹693 cr, up 23% YoY from ₹566 cr in Q2 FY26, down 2% QoQ from ₹704 cr in Q1 FY27 |
| Consolidated EBITDA | ₹138 cr, down 24% YoY from ₹183 cr in Q2 FY26 |
| Consolidated PAT | ₹187 cr (H1 FY27), down 15% YoY from ₹219 cr in H1 FY26 |
| EBITDA margin | 21%, impacted by ATBS sales shift from Q2 to Q3 and logistics, power costs not fully passed through |
| FY27 top-line growth guidance | 20%–25% improvement over FY26 |
| FY27 EBITDA margin guidance | 24%–25% |
| FY28 EBITDA margin expectation | 25%–26% |
| ATBS revenue share | 27%–28% of top line (H1 FY27) |
| IBB revenue share | 12%–15% of top line (H1 FY27) |
| Butyl Phenols revenue share | 16%–20% of top line (H1 FY27) |
| Antioxidants revenue share | 15%–17% of top line (H1 FY27) |
| Announced capex plan | ₹500 cr for new specialty chemicals, commercialization in two years, funded through internal accruals |
| Additional capex planned | ₹500 cr, land acquisition underway, more clarity in next couple of months, funded through internal accruals |
| New capex expected asset turnover | 1:1 to 1.5x |
| New capex expected ROI | 15%–20% |
| New products average realization | ~$3 per kg, range $2–$4.5 per kg |
| New products export share | 65%–70% |
| VOPL revenue expectation for FY27 | ₹75 cr–₹100 cr, will not cross ₹100 cr this financial year |